1. Summary
Advantages
- Current debt level 22.35% is below 100% and has decreased over 5 years from 28.74%.
Disadvantages
- Price (135.9 $) is higher than fair price (70.2 $)
- Dividends (0%) are below the sector average (1.3922%).
- The stock's return over the last year (-6.98%) is lower than the sector average (8.81%).
- The company's current efficiency (ROE=-18.81%) is lower than the sector average (ROE=11.52%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Illumina | Healthcare | Index | |
|---|---|---|---|
| 7 days | 10.9% | -7.3% | 5.6% |
| 90 days | 24.6% | -0.7% | 0.2% |
| 1 year | -7% | 8.8% | 27% |
ILMN vs Sector: Illumina has significantly underperformed the "Healthcare" sector by -15.79% over the past year.
ILMN vs Market: Illumina has significantly underperformed the market by -33.93% over the past year.
Stable price: ILMN is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: ILMN with weekly volatility of -0.1343% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (135.9 $) is higher than the fair price (70.2 $).
Price is higher than fair: The current price (135.9 $) is 48.3% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (39.92) is lower than that of the sector as a whole (47.96).
P/E vs Market: The company's P/E (39.92) is lower than that of the market as a whole (54.77).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (3.85) is lower than that of the sector as a whole (4.81).
P/BV vs Market: The company's P/BV (3.85) is higher than that of the market as a whole (2.3).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (4.91) is lower than that of the sector as a whole (33.73).
P/S vs Market: The company's P/S indicator (4.91) is lower than that of the market as a whole (9.99).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-21.83) is higher than that of the sector as a whole (-22.5).
EV/Ebitda vs Market: The company's EV/Ebitda (-21.83) is lower than that of the market as a whole (22.24).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Ebitda
Yield Trend: Negative and has fallen by -43.22% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-43.22%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-9.58%).
5.4. ROE
ROE vs Sector: The company's ROE (-18.81%) is lower than that of the sector as a whole (11.52%).
ROE vs Market: The company's ROE (-18.81%) is lower than that of the market as a whole (31.8%).
5.5. ROA
ROA vs Sector: The company's ROA (-10.38%) is lower than that of the sector as a whole (0.7317%).
ROA vs Market: The company's ROA (-10.38%) is lower than that of the market as a whole (7.12%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (6.96%) is lower than that of the sector as a whole (7.57%).
ROIC vs Market: The company's ROIC (6.96%) is lower than that of the market as a whole (10.68%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.3922%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 22.06.2023 | TOUSI SUSAN H SVP, Chief Commercial Officer |
Sale | 200 | 100 000 | 500 |
| 22.02.2023 | Aravanis Alexander SVP, Chief Technology Officer |
Sale | 201.74 | 1 088 990 | 5398 |
| 21.02.2023 | Aravanis Alexander SVP, Chief Technology Officer |
Purchase | 202.2 | 1 878 840 | 9292 |
| 28.03.2022 | Dadswell Charles SVP & General Counsel |
Sale | 342.83 | 126 161 | 368 |
| 30.08.2021 | TOUSI SUSAN H SVP, Chief Commercial Officer |
Sale | 463.5 | 139 050 | 300 |
Оплатите подписку
Больше функциональности и данных для анализа компаний и портфеля доступно по подписке
